Skip to main content

Rakesh Jhunjhunwala, Damani, Ashish Kacholia & Vijay Kedia each have at least 1 of these four stocks in their portfolio

 Karur Vysya Bank fell more than 40% so far in the year 2020, and Prozone Intu Properties fell by about 20%. On the other hand, Birlasoft rose 70% while Vaibhav Global rallied by about 90% in the same period.

 

The big bulls of D-Street are known for their liking of small & midcap themes. Despite the widening gap between the broader market and frontliners over the last two years, the who's who of D-Street have maintained their staunch belief in the small & midcap story.

Moneycontrol has collated a list of four stocks that are common in the portfolios of at least two big investors. We have taken reference from the portfolio of Rakesh Jhunjhunwala, Radhakishan Damani, Ashish Kacholia, Ashish Dhawan and Vijay Kedia.

Stocks that are common across big investor portfolios include names like Karur Vysya Bank, Prozone Intu Properties, Vaibhav Global, and Birlasoft.

Karur Vysya Bank has fallen more than 40 percent so far in 2020 and Prozone Intu Properties is down 20 percent. On the other hand, Birlasoft rose 70 percent this year, while Vaibhav Global rallied by about 90 percent in the same period.


Experts are of the view that the recovery in the broader market space is underway and there is a higher possibility that mid & smallcap stocks could outperform the largecaps in the near future.

“We believe that the broader market recovery is underway and expect an improved performance from midcaps. Our study of past market corrections indicate that midcaps outperform largecaps in the later stages of market recovery,” Elara Capital said in a report.

The brokerage further added that the weight distribution is more diverse in the midcap index relative to Nifty and is favourably disposed towards pharma, healthcare services, auto and industrials which they believe augurs well for its outperformance amid favorable price support and valuations, added the note.

Karur Vysya Bank which fell by about 40 percent and Birlasoft which rallied 70 percent so far in 2020 have reported strong earnings in the June quarter.

Last month Karur Vysya Bank (KVB) reported a healthy 45 percent jump in the net profit at Rs 105.50 crore in the first quarter of the current fiscal on fall in bad loans.

Asset quality improved, with gross non-performing assets (NPAs) falling to 8.34 percent of gross advances as on June 30, 2020, from 9.17 percent a year ago.

Birlasoft hit a fresh 52-week high in August after the company reported a nearly 35 percent rise in consolidated net profit for Q1 FY21. Birlasoft is a part of the $2 billion diversified C K Birla Group.

The company posted a profit of Rs 41.8 crore for April-June 2019, Birlasoft said in a regulatory filing. Revenue from operations grew 17.7 percent to Rs 914.6 crore in the period under review from Rs 777.2 crore in the year-ago period.

Vaibhav Global, which is a multi-national electronic retailer, wholesaler and manufacturer of fashion jewellery and lifestyle accessories, reported a healthy jump of 47 percent YoY in net profit for the June quarter to Rs 53 crore, compared to Rs 36 crore reported in the year-ago period.

Prozone Intu has been set up to create, develop and manage world-class regional shopping centres and associated mixed-use developments pan-India. Its partner Intu Properties Plc, UK owns and manage 12 of the top 20 UK Shopping Centre.

While the June quarter results are awaited, the March quarter results showed over 70 percent decline in the profit on a year-on-year basis.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com/SD Solutions advises users to check with certified experts before taking any investment decisions.

Source- Moneycontrol.com

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more